Compare DexCom, Inc. (DXCM) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Johnson Controls International PLC — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Johnson Controls International PLC trades at $157.44 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 2.9× DexCom, Inc.'s market cap, and Johnson Controls International PLC pays a 1.04% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Johnson Controls International PLC for 65 Days on average.
| DXCM | JCI | |
|---|---|---|
Market Cap | $31.86B | $93.28B |
Volume | 3,607,070 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $158.76 |
52-Week Low | $54.84 | $105.55 |
Typical Hold Time | 62 Days | 65 Days |
Enterprise Value | $31.32B | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
